Bismuth not just for ulcers; Dr. Nano X

> Bismuth: It's not just for ulcers anymore. A bismuth citrate-based complex is a potential vehicle for drug delivery. Article

> Nevin Daniel, a senior at Ward Melville High School in East Setauket, NY, was first runner up in the individual category in the 2010 Siemens High School Competition in Math, Science & Technology. Daniel was awarded a $50,000 scholarship for his project to develop a new method for anti-cancer drug delivery using novel asymmetrical bow-tie PAMAM dendrimer conjugates. Release

> Celator Pharmaceuticals reports that elderly patients with newly diagnosed acute myeloid leukemia (AML) treated with the company's CPX-351 (Cytarabine:Daunorubicin) liposome injection showed improvements in Phase 2 studies. According to Celator, CPX-351, which has been granted orphan drug status by the FDA for treatment of AML, represents a new approach to developing combinations of drugs in which drug molar ratios with synergistic anti-tumor activity are encapsulated in a drug delivery vehicle in order to maintain the desired ratio following administration. Celator release

> A Finnish SME has developed a biodegradable drug delivery technology for small molecule drugs and is looking for partners. Item

> A table summarizes the product pipeline maturity of North Carolina-based nanobio companies, including many involved in drug delivery. Download the PDF

> Drug delivery abstract of the week: Unique benefits of nanotechnology to drug delivery and diagnostics Abstract

> Drug delivery patent application of the week: Drug delivery systems using FC fragments Patent Application

> And Finally... Dr. Nano X--a video game in which therapeutic medicine comes from the barrel of a nanosize gun in the hands of Dr. Nano, who blows the bad diseases away--is coming to the iPhone. Report

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.